LCZ-Mont Kid Tablet is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg, formulated specifically for pediatric use. Levocetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, effectively reducing symptoms of allergic rhinitis such as sneezing, nasal congestion, and rhinorrhea by blocking histamine action. Montelukast is a leukotriene receptor antagonist that prevents leukotriene-mediated bronchoconstriction, inflammation, and mucus production, thereby improving respiratory function in conditions like asthma and allergic rhinitis. The synergistic effect of these two active ingredients provides comprehensive relief from allergic symptoms and helps in the management of asthma in children. LCZ-Mont Kid Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, as well as for the prophylaxis and chronic treatment of asthma in pediatric patients. It is generally well tolerated, with a low incidence of sedation or other adverse effects commonly associated with first-generation antihistamines. Dosage should be administered as prescribed by a healthcare professional, considering the child’s age and clinical condition. Regular monitoring is advised to assess therapeutic efficacy and detect any potential side effects.